JP3247048U - Water-soluble oxide wound dressing manufacturing equipment - Google Patents
Water-soluble oxide wound dressing manufacturing equipment Download PDFInfo
- Publication number
- JP3247048U JP3247048U JP2024001028U JP2024001028U JP3247048U JP 3247048 U JP3247048 U JP 3247048U JP 2024001028 U JP2024001028 U JP 2024001028U JP 2024001028 U JP2024001028 U JP 2024001028U JP 3247048 U JP3247048 U JP 3247048U
- Authority
- JP
- Japan
- Prior art keywords
- water
- oxide
- aqueous solution
- salt aqueous
- wound dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 150000005324 oxide salts Chemical class 0.000 claims abstract description 52
- 239000007864 aqueous solution Substances 0.000 claims abstract description 51
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 238000001179 sorption measurement Methods 0.000 claims abstract description 24
- 238000003860 storage Methods 0.000 claims abstract description 23
- 239000012153 distilled water Substances 0.000 claims abstract description 20
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 16
- 239000011707 mineral Substances 0.000 claims abstract description 16
- 230000005415 magnetization Effects 0.000 claims abstract description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 11
- 239000001301 oxygen Substances 0.000 claims abstract description 11
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 10
- 238000005868 electrolysis reaction Methods 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000000654 additive Substances 0.000 claims description 12
- 230000000996 additive effect Effects 0.000 claims description 12
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 230000005684 electric field Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 10
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 238000013268 sustained release Methods 0.000 abstract description 4
- 239000012730 sustained-release form Substances 0.000 abstract description 4
- 239000013078 crystal Substances 0.000 abstract description 3
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 98
- 208000027418 Wounds and injury Diseases 0.000 description 98
- 210000001519 tissue Anatomy 0.000 description 10
- 230000029663 wound healing Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000000416 exudates and transudate Anatomy 0.000 description 8
- 238000011587 new zealand white rabbit Methods 0.000 description 8
- 239000012266 salt solution Substances 0.000 description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000010413 sodium alginate Nutrition 0.000 description 7
- 239000000661 sodium alginate Substances 0.000 description 7
- 229940005550 sodium alginate Drugs 0.000 description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 7
- 230000001338 necrotic effect Effects 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 4
- 239000003248 enzyme activator Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010051814 Eschar Diseases 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 231100000333 eschar Toxicity 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 102000034240 fibrous proteins Human genes 0.000 description 3
- 108091005899 fibrous proteins Proteins 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 210000001640 nerve ending Anatomy 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【課題】被覆材が活性成分を保護する効果と徐放効果とを有する水溶性酸化物傷口被覆材の製造装置を提供する。【解決手段】水溶性酸化物傷口被覆材の製造装置は、収容槽11、活性炭吸着フィルター12、流量制御弁14及び磁化反応器15を備える。収容槽には蒸留水又は鉱泉水を収容し、蒸留水又は鉱泉水に酸化物塩類水溶液を加え、収容槽中で希釈酸化物塩類水溶液を生成する。酸化物塩類水溶液は加熱電解法により高圧酸素を結晶塩水溶液に通して形成する。活性炭吸着フィルターは収容槽に接続し、希釈酸化物塩類水溶液中の微量な疎水性有害物質を除去する。流量制御弁は活性炭吸着フィルターで濾過した後の希釈酸化物塩類水溶液の出力流量を制御する。磁化反応器は流量制御弁と接続し、希釈酸化物塩類水溶液を合成反応させて濃縮活性酸化物水を生成し、濃縮活性酸化物水を水溶性高分子151及び蒸留水に加えて水溶性酸化物傷口被覆材を形成する。【選択図】図2[Problem] To provide an apparatus for manufacturing a water-soluble oxide wound dressing in which the dressing has an effect of protecting an active ingredient and an effect of sustained release. [Solution] The apparatus for manufacturing a water-soluble oxide wound dressing comprises a storage tank 11, an activated carbon adsorption filter 12, a flow control valve 14, and a magnetization reactor 15. The storage tank stores distilled water or mineral water, and an oxide salt aqueous solution is added to the distilled water or mineral water to produce a diluted oxide salt aqueous solution in the storage tank. The oxide salt aqueous solution is formed by passing high-pressure oxygen through a crystal salt aqueous solution by a heating electrolysis method. The activated carbon adsorption filter is connected to the storage tank and removes traces of hydrophobic harmful substances in the diluted oxide salt aqueous solution. The flow control valve controls the output flow rate of the diluted oxide salt aqueous solution after filtering through the activated carbon adsorption filter. The magnetization reactor is connected to the flow control valve and causes a synthetic reaction of the diluted oxide salt aqueous solution to produce a concentrated activated oxide aqueous solution, and the concentrated activated oxide aqueous solution is added to a water-soluble polymer 151 and distilled water to form a water-soluble oxide wound dressing. [Selected Figure] Fig. 2
Description
本考案は、水溶性酸化物傷口被覆材の製造装置に関し、特に、製造する被覆材が活性成分を保護する効果と徐放効果とを有する、水溶性酸化物傷口被覆材の製造装置に関する。 This invention relates to an apparatus for manufacturing a water-soluble oxide wound dressing, and in particular to an apparatus for manufacturing a water-soluble oxide wound dressing that produces a dressing that has the effect of protecting an active ingredient and the effect of sustained release.
皮膚は、脊椎動物の軟層を覆う身体の器官の中で最大のものであり、外部からの侵入を防ぎ、水分を保持し、保温、バリア及び感覚の機能を有する。そのため、皮膚に傷口がある場合、例えば、一般の創傷又は褥瘡により形成された傷口は、皮膚が悪影響を受け、正常にあるべき機能を発揮できないことがあった。 The skin is the largest of the organs that cover the soft layers of the body of vertebrates, and has the functions of preventing invasion from the outside, retaining moisture, and providing heat, as a barrier, and of sensation. Therefore, when there is a wound on the skin, for example a wound formed by a general wound or a bedsore, the skin can be adversely affected and unable to perform the functions that it should normally perform.
従来から市販されている傷口被覆材は種類が多く、一般に傷口の性質に応じて適切な傷口被覆材を選択して傷口の癒合環境を良好にし、異物から隔離して環境中の各種細菌、ウイルスが傷口から侵入して感染してしまうことを防いでいた。従来の傷口処理は、まず、傷口を消毒してから塗り薬を塗ってガーゼで覆い、傷口が自然に癒合するのを待った後、ガーゼなど外側を覆って固定されていた材料を取り除いた。しかし、この従来の方式は、傷口の面積が大きいか患者の体質により、完治が困難な患者(例えば、糖尿病患者)の場合、傷口が元の状態に戻るまでの時間が長くなってしまう上、薬を何度も交換しなければならなかった。また、薬を交換するためにガーゼなどを取り除く際、ガーゼなどの被覆材に傷口の組織液が粘着し、傷口が外力により裂けて傷つき、癒合にかかる時間が長引いてしまうことがあった。 There are many types of wound dressings available on the market, and generally, the appropriate wound dressing is selected according to the nature of the wound to improve the wound healing environment, isolate the wound from foreign bodies, and prevent various bacteria and viruses in the environment from entering the wound and causing infection. Conventional wound treatment involves first disinfecting the wound, applying an ointment, covering it with gauze, waiting for the wound to heal naturally, and then removing the gauze or other material that was covering and fixing the wound. However, this conventional method can be difficult for patients with large wound areas or difficult to heal due to their constitution (e.g., diabetic patients), as it takes a long time for the wound to return to its original state and the medicine must be changed many times. In addition, when removing the gauze to change the medicine, tissue fluid from the wound can stick to the gauze or other dressing, causing the wound to tear and be damaged by external forces, which can prolong the time it takes for the wound to heal.
本考案の課題は、製造装置で製造した水溶性酸化物傷口被覆材が壊死組織及び繊維タンパクの溶解にとって有利であり、滲出液中の多種の成長因子の放出を促進させ、局部的に湿潤状態にし、結痂の形成を減らし、新生肉芽組織の機械性損傷を防ぎ、被覆材を交換する際の損傷及び疼痛を低減させ、密閉性保湿環境を形成し、被覆材でバリアを形成し、傷口から感染するリスクを減らし、創面の神経末梢を保護して疼痛を低減させることができるとともに、創面を恒温状態に維持し、細胞分裂を加速させて創面の癒合を促進させることができ、水溶性酸化物傷口被覆材が活性成分を保護する効果と徐放効果とを有する、水溶性酸化物傷口被覆材の製造装置を提供することにある。
The objective of the present invention is to provide a manufacturing device for a water-soluble oxide wound dressing, which produces a water-soluble oxide wound dressing that is beneficial for dissolving necrotic tissue and fibrous protein, promotes the release of various growth factors in exudate, creates a localized moist state, reduces the formation of eschars, prevents mechanical damage to newly formed granulation tissue, reduces damage and pain when changing the dressing, creates an airtight moist environment, forms a barrier with the dressing, reduces the risk of infection from the wound, protects the nerve endings of the wound surface and reduces pain, maintains the wound surface at a constant temperature, accelerates cell division and promotes wound healing, and the water-soluble oxide wound dressing has the effect of protecting the active ingredient and the effect of sustained release.
上述の目的を達成するため、請求項1の考案にかかる水溶性酸化物傷口被覆材の製造装置は、収容槽、活性炭吸着フィルター、流量制御弁及び磁化反応器を備えた、水溶性酸化物傷口被覆材の製造装置であって、前記収容槽には、蒸留水又は鉱泉水を収容し、前記蒸留水又は前記鉱泉水に酸化物塩類水溶液を加え、前記収容槽中で希釈酸化物塩類水溶液を生成し、前記酸化物塩類水溶液は、加熱電解法により高圧酸素を結晶塩水溶液に通して形成し、前記活性炭吸着フィルターは、前記収容槽に接続し、前記活性炭吸着フィルターにより、前記希釈酸化物塩類水溶液中の微量な疎水性有害物質を除去し、前記流量制御弁は、前記活性炭吸着フィルターと接続し、前記活性炭吸着フィルターで濾過した後の前記希釈酸化物塩類水溶液の出力流量を制御し、前記磁化反応器は、前記流量制御弁と接続し、前記流量制御弁が出力した前記希釈酸化物塩類水溶液を受け、前記希釈酸化物塩類水溶液を合成反応させて濃縮活性酸化物水を生成し、前記濃縮活性酸化物水を水溶性高分子及び前記蒸留水に加えて水溶性酸化物傷口被覆材を形成することを特徴とする。 In order to achieve the above-mentioned object, the manufacturing device for water-soluble oxide wound dressing according to the invention of claim 1 is a manufacturing device for water-soluble oxide wound dressing comprising a storage tank, an activated carbon adsorption filter, a flow control valve, and a magnetization reactor, and the storage tank stores distilled water or mineral water, and an oxide salt aqueous solution is added to the distilled water or the mineral water to generate a diluted oxide salt aqueous solution in the storage tank, and the oxide salt aqueous solution is formed by passing high-pressure oxygen through a crystal salt aqueous solution by a heating electrolysis method, and the activated carbon adsorption filter is connected to the storage tank, and the activated carbon adsorption filter removes traces of hydrophobic harmful substances in the diluted oxide salt aqueous solution, and the flow control valve is connected to the activated carbon adsorption filter and controls the output flow rate of the diluted oxide salt aqueous solution after filtering with the activated carbon adsorption filter, and the magnetization reactor is connected to the flow control valve, receives the diluted oxide salt aqueous solution output by the flow control valve, and causes a synthetic reaction of the diluted oxide salt aqueous solution to generate concentrated activated oxide water, and adds the concentrated activated oxide water to a water-soluble polymer and the distilled water to form a water-soluble oxide wound dressing.
請求項2の考案にかかる水溶性酸化物傷口被覆材の製造装置は、前記磁化反応器は、0.1～1テスラ(Tesla)の磁場と、10～100ボルト/cmの電界とを有することを特徴とする。 The apparatus for producing water-soluble oxide wound dressings according to the invention of claim 2 is characterized in that the magnetization reactor has a magnetic field of 0.1 to 1 Tesla and an electric field of 10 to 100 volts/cm.
請求項3の考案にかかる水溶性酸化物傷口被覆材の製造装置は、前記収容槽と前記活性炭吸着フィルターとの間には、添加剤槽を接続し、前記収容槽中で生成した前記希釈酸化物塩類水溶液を前記添加剤槽に導入し、オゾンを前記添加剤槽中に加えて殺菌することを特徴とする。 The manufacturing device for water-soluble oxide wound dressing material according to the invention of claim 3 is characterized in that an additive tank is connected between the storage tank and the activated carbon adsorption filter, the diluted oxide salt aqueous solution produced in the storage tank is introduced into the additive tank, and ozone is added to the additive tank for sterilization.
請求項4の考案にかかる水溶性酸化物傷口被覆材の製造装置は、前記流量制御弁は、前記希釈酸化物塩類水溶液の流速を500～8000L/分の範囲に制御することを特徴とする。 The device for producing water-soluble oxide wound dressing material according to the invention of claim 4 is characterized in that the flow control valve controls the flow rate of the diluted oxide salt aqueous solution to a range of 500 to 8000 L/min.
本考案に係る水溶性酸化物傷口被覆材の製造装置は、製造装置で製造した水溶性酸化物傷口被覆材が壊死組織及び繊維タンパクの溶解にとって有利であり、滲出液中の多種の成長因子の放出を促進させ、局部的に湿潤状態にし、結痂の形成を減らし、新生肉芽組織の機械性損傷を防ぎ、被覆材を交換する際の損傷及び疼痛を低減させ、密閉性保湿環境を形成し、被覆材でバリアを形成し、傷口から感染するリスクを減らし、創面の神経末梢を保護して疼痛を低減させることができるとともに、創面を恒温状態に維持し、細胞分裂を加速させて創面の癒合を促進させることができ、水溶性酸化物傷口被覆材が活性成分を保護する効果と徐放効果とを有する。 The water-soluble oxide wound dressing manufacturing device according to the present invention produces a water-soluble oxide wound dressing that is beneficial for dissolving necrotic tissue and fibrous protein, promotes the release of various growth factors in exudate, creates a localized moist state, reduces the formation of eschars, prevents mechanical damage to newly formed granulation tissue, reduces damage and pain when changing dressings, creates an airtight moist environment, forms a barrier with the dressing, reduces the risk of infection from the wound, protects the nerve endings of the wound and reduces pain, maintains the wound at a constant temperature, accelerates cell division and promotes wound healing, and the water-soluble oxide wound dressing has the effect of protecting the active ingredient and the effect of sustained release.
本考案に係る水溶性酸化物傷口被覆材の製造装置について、当業者が本考案の目的、特徴及び効果を完全に理解することを可能にするために、以下、適切な実施形態を列挙するとともに、添付の図面と併せて、本考案の技術的内容を詳細に説明する。 In order to enable those skilled in the art to fully understand the objectives, features, and effects of the present invention, the following describes in detail the technical content of the present invention with reference to the accompanying drawings and examples of suitable embodiments of the present invention.
図1及び図2を参照する。図1及び図2に示すように、本考案の一実施形態に係る水溶性酸化物傷口被覆材の製造装置は、収容槽11、活性炭吸着フィルター12、流量制御弁14及び磁化反応器15を備える。
Refer to Figures 1 and 2. As shown in Figures 1 and 2, an apparatus for producing a water-soluble oxide wound dressing according to one embodiment of the present invention includes a
収容槽11には、蒸留水又は鉱泉水を収容し、蒸留水又は鉱泉水に酸化物塩類水溶液(oxide salt solution)を加えると、収容槽11中に希釈酸化物塩類水溶液が生成される。酸化物塩類水溶液は、加熱電解法により高圧酸素を結晶塩水溶液に通して形成する。
The
活性炭吸着フィルター12は、収容槽11に接続し、活性炭吸着フィルター12により希釈酸化物塩類水溶液中の微量な疎水性有害物質を除去する。
The activated
流量制御弁14は、活性炭吸着フィルター12と接続し、活性炭吸着フィルター12で濾過した後の希釈酸化物塩類水溶液の出力流量を制御する。
The
磁化反応器15は、流量制御弁14と接続し、流量制御弁14が出力した希釈酸化物塩類水溶液を受け、希釈酸化物塩類水溶液を合成反応させて濃縮活性酸化物水を生成する。濃縮活性酸化物水を水溶性高分子151及び蒸留水に加えて水溶性酸化物傷口被覆材を形成する。
The
本考案の一実施形態において、磁化反応器15は、0.1～1テスラ(Tesla)の磁場と、10～100ボルト/cmの電界とを有する。
In one embodiment of the invention, the
図3を参照する。図3に示すように、本考案の一実施形態において、収容槽11と活性炭吸着フィルター12との間には、添加剤槽16を接続し、収容槽11中で生成した希釈酸化物塩類水溶液を添加剤槽16に導入し、オゾンを添加剤槽16中に加えて殺菌する。
Refer to Figure 3. As shown in Figure 3, in one embodiment of the present invention, an
オゾンは、希釈酸化物塩類溶液に対して殺菌ステップを行う。 Ozone performs a disinfection step on dilute oxide salt solutions.
本考案の一実施形態において、流量制御弁14は、希釈酸化物塩類水溶液の流速を500～8000L/分の範囲に制御する。
In one embodiment of the present invention, the
図1及び図2を参照する。図1及び図2に示すように、本考案の製造方法は、以下のステップS101～S105を含む。 Please refer to Figures 1 and 2. As shown in Figures 1 and 2, the manufacturing method of the present invention includes the following steps S101 to S105.
ステップS101: 収容槽11中に蒸留水又は鉱泉水を準備する。
Step S101: Prepare distilled water or mineral water in the
ステップS102: 酸化物塩類水溶液を蒸留水又は鉱泉水に加え、希釈酸化物塩類水溶液を生成する。酸化物塩類水溶液は、加熱電解法により高圧酸素を結晶塩水溶液に通して形成する。酸化物塩類水溶液は、約5.5～8のPH値及び5～50mol/Lの体積モル濃度を有する。酸化物塩類水溶液は、10～40mol/Lの体積モル濃度を有することが好ましいが、15～35mol/Lの体積モル濃度を有すればより好ましい。加熱電解法の加熱温度は、40～80℃の範囲に制御する。酸化物塩類水溶液は、金属元素陽イオンと、炭酸根、硫酸根、クロム酸根、タングステン酸根、モリブデン酸根、リン酸根、ヒ酸根又はバナジン酸根とを化合させて生成した水溶液である。金属元素陽イオンは、少なくとも1種の2価又は3価の金属陽イオン又はこれらの組み合わせである。金属元素陽イオンは、好ましくはFe2+、Cu2+、Zn2+、Pb2+、Mn2+又はBi3+である。 Step S102: The oxide salt aqueous solution is added to distilled water or mineral water to produce a diluted oxide salt aqueous solution. The oxide salt aqueous solution is formed by passing high pressure oxygen through the crystal salt aqueous solution by thermal electrolysis. The oxide salt aqueous solution has a pH value of about 5.5 to 8 and a volume molar concentration of 5 to 50 mol/L. The oxide salt aqueous solution preferably has a volume molar concentration of 10 to 40 mol/L, more preferably a volume molar concentration of 15 to 35 mol/L. The heating temperature of the thermal electrolysis is controlled in the range of 40 to 80°C. The oxide salt aqueous solution is an aqueous solution produced by combining a metal element cation with a carbonate radical, a sulfate radical, a chromate radical, a tungstate radical, a molybdate radical, a phosphate radical, an arsenate radical, or a vanadate radical. The metal element cation is at least one kind of divalent or trivalent metal cation or a combination thereof. The metal element cation is preferably Fe 2+ , Cu 2+ , Zn 2+ , Pb 2+ , Mn 2+ or Bi 3+ .
ステップS103: 希釈酸化物塩類水溶液を活性炭吸着フィルター12に通し、微量な疎水性有害物質を除去する。
Step S103: The diluted oxide salt aqueous solution is passed through the activated
ステップS104: 流量制御弁14を介して希釈酸化物塩類水溶液を磁化反応器15中に導入し、合成反応を行う。磁化反応器15は、0.1～1テスラ(Tesla)の磁場と、10～100ボルト/cmの電界とを有する。そのため、希釈酸化物塩類水溶液が磁化反応器15を通過すると、水分子中の帯電粒子が磁場及び電界の作用を受けて運動が発生し、水分子中の水素結合が切れ、水素結合により酸化物塩類を覆う。また、磁化反応器15の合成温度を10℃～55℃の範囲に制御し、合成圧力を6kg/cm2～9kg/cm2の範囲に制御する。合成時間を30～90分間にして希釈活性酸化物水を生成する。
Step S104: The diluted oxide salt aqueous solution is introduced into the
ステップS105: 希釈活性酸化物水を65～70℃に加熱し、水溶性高分子151と、蒸留水又は鉱泉水とを加えて3.5～4.5時間撹拌する。この撹拌の回転数は600～650回転/分であり、さらに真空状態下で5～6時間撹拌し、水溶性酸化物傷口被覆材を形成する。水溶性酸化物傷口被覆材の総重量パーセントは、45.0～55.0%の蒸留水又は鉱泉水、15.0～25.0%の酸化物塩類水溶液及び30.0～35.0%の水溶性高分子151を含む。水溶性高分子151は、アルギン酸ナトリウム、ポリビニルピロリドン、カルボキシメチルセルロースナトリウム、ヒアルロン酸又はこれらの組み合わせからなる。水溶性高分子151は、水溶性酸化物傷口被覆材の総重量パーセントで、1.0～30.0%のアルギン酸ナトリウム、1.0～25.0%のポリビニルピロリドン及び1.0～25.0%のカルボキシメチルセルロースナトリウムを含む。水溶性酸化物傷口被覆材の厚さは、0.1mm以上、4mm以下である。
Step S105: The diluted active oxide water is heated to 65-70°C, and the water-
本考案が製造する水溶性酸化物傷口被覆材には、三次元網状水性ゲル分子技術を利用する。この技術的特徴は、水ゲル高分子を互いに連結して空間網状構造を形成し、網状構造の孔質中に液体を充満させる。架橋反応を発生させるゲルは、共有架橋結合(covalent cross-linking)を形成するため、ゲル特性により膨潤するが溶解しない。水ゲルの大量の親水性基により、大量の水分を吸収して保持することができるため、本考案の活性酸化物ゲルは、生体適合性及び生分解性に優れて合成が容易であり、低分子溶質に対して良好な透過性を有する。 The water-soluble oxide wound dressing produced by this invention utilizes three-dimensional network aqueous gel molecular technology. This technology is characterized by forming a spatial network structure by linking aqueous gel polymers to each other, and filling the pores of the network structure with liquid. The gel that generates the cross-linking reaction forms covalent cross-linking, so it swells due to its gel properties but does not dissolve. The large amount of hydrophilic groups in the aqueous gel allows it to absorb and retain large amounts of water, so the active oxide gel of this invention is easy to synthesize, has excellent biocompatibility and biodegradability, and has good permeability to low molecular weight solutes.
(傷口癒合テスト)
実験では、生後8週間の雄のニュージーランド産白うさぎを使用し、その体重は約2000～2500gであった。室温を22℃に維持して相対湿度を45%に維持した独立空調の動物部屋の中で全ての実験動物を飼養し、水分及び飼料を十分に与えた。実験を行う前には、実験動物を少なくとも4週間かけて環境に適応させた。実験動物の飼養環境、処理及び一切の実験プロトコルは、台湾国家衛生研究院(National Institutes of Health: NIH)の実験動物飼養管理及び使用規範(Guide for the Care and Use of Laboratory Animals)を満たした。
(Wound healing test)
Male New Zealand white rabbits, 8 weeks old and weighing approximately 2000-2500g, were used in the experiments. All experimental animals were housed in an independently air-conditioned animal room with a room temperature maintained at 22°C and a relative humidity of 45%, and were provided with sufficient water and food. Before experiments, the animals were allowed to acclimate to the environment for at least 4 weeks. The animal housing environment, treatment, and all experimental protocols complied with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH), Taiwan.
(皮膚傷口の形成)
ニュージーランド産白うさぎの背中部分を剃毛してから、ヨードチンキ及び70%のアルコールで消毒した後、ニュージーランド産白うさぎの背中の皮膚を、メスを使用して約2cm×2cmの面積、約2～3mmの深さで切って傷口をつくった。
(Skin wound formation)
The back of a New Zealand white rabbit was shaved and disinfected with iodine tincture and 70% alcohol. The skin on the back of the rabbit was then incised with a scalpel to create a wound measuring approximately 2 cm x 2 cm and approximately 2 to 3 mm deep.
(水溶性酸化物傷口被覆材の成分含量)
実験群1: 水溶性酸化物傷口被覆材は、水溶性酸化物傷口被覆材の総重量パーセントで、55.0%の蒸留水又は鉱泉水、15.0%の酸化物塩類水溶液、3.0%のアルギン酸ナトリウム、2.0%のポリビニルピロリドン及び25.0%のカルボキシメチルセルロースナトリウムを含む。
(Component content of water-soluble oxide wound dressing material)
Experimental Group 1: The water-soluble oxide wound dressing contained, by total weight percentage of the water-soluble oxide wound dressing, 55.0% distilled water or mineral water, 15.0% oxide salt aqueous solution, 3.0% sodium alginate, 2.0% polyvinylpyrrolidone, and 25.0% sodium carboxymethylcellulose.
実験群2: 水溶性酸化物傷口被覆材は、水溶性酸化物傷口被覆材の総重量パーセントで、55.0%の蒸留水又は鉱泉水、20.0%の酸化物塩類水溶液、3.0%のアルギン酸ナトリウム、2.0%のポリビニルピロリドン及び20.0%のカルボキシメチルセルロースナトリウムを含む。 Experimental Group 2: The water-soluble oxide wound dressing contained, by total weight percentage of the water-soluble oxide wound dressing, 55.0% distilled water or mineral water, 20.0% oxide salt aqueous solution, 3.0% sodium alginate, 2.0% polyvinylpyrrolidone, and 20.0% sodium carboxymethylcellulose.
対照群1: 水溶性酸化物傷口被覆材は、水溶性酸化物傷口被覆材の総重量パーセントで、55.0%の蒸留水又は鉱泉水、15.0%の酸化物塩類水溶液、3.0%のアルギン酸ナトリウム、2.0%のポリビニルピロリドン及び25.0%のカルボキシメチルセルロースナトリウムを含む。 Control Group 1: The water-soluble oxide wound dressing contained, by total weight percentage of the water-soluble oxide wound dressing, 55.0% distilled water or mineral water, 15.0% oxide salt aqueous solution, 3.0% sodium alginate, 2.0% polyvinylpyrrolidone, and 25.0% sodium carboxymethylcellulose.
対照群2: 水溶性酸化物傷口被覆材は、水溶性酸化物傷口被覆材の総重量パーセントで、55.0%の蒸留水又は鉱泉水、20.0%の酸化物塩類水溶液、3.0%のアルギン酸ナトリウム、2.0%のポリビニルピロリドン及び20.0%のカルボキシメチルセルロースナトリウムを含む。 Control Group 2: The water-soluble oxide wound dressing contained, by total weight percentage of the water-soluble oxide wound dressing, 55.0% distilled water or mineral water, 20.0% oxide salt aqueous solution, 3.0% sodium alginate, 2.0% polyvinylpyrrolidone, and 20.0% sodium carboxymethylcellulose.
(水溶性酸化物傷口被覆材の貼付)
ニュージーランド産白うさぎを2つの実験群と2つの対照群とにランダムに分けた。各群のニュージーランド産白うさぎは、上述した方式により皮膚に傷口を形成してから、実験群1及び実験群2のニュージーランド産白うさぎの皮膚の傷口上に、上述した実験群1及び実験群2の水溶性酸化物傷口被覆材を貼付し、動物の傷口上をポリウレタン(polyurethane: PU)防水フィルムで覆って湿潤状態を保持した。対照群1及び対照群2のニュージーランド産白うさぎは、上述した方式により皮膚に傷口を形成してから、対照群1及び対照群2のニュージーランド産白うさぎの皮膚の傷口に、上述した対照群1及び対照群2の水溶性酸化物傷口被覆材を貼付した。実験は全体で14日間行い、被覆材を貼付してから2日目、6日目、10日目及び14日目に、各群のニュージーランド産白うさぎの傷口の面積を測定した結果を以下の表1に示す。
(Application of water-soluble oxide wound dressing)
New Zealand white rabbits were randomly divided into two experimental groups and two control groups. After wounds were formed on the skin of New Zealand white rabbits in each group by the above-mentioned method, the water-soluble oxide wound dressings of experimental groups 1 and 2 were applied to the wounds on the skin of New Zealand white rabbits in experimental groups 1 and 2, and the wounds of the animals were covered with polyurethane (PU) waterproof film to keep them moist. After wounds were formed on the skin of New Zealand white rabbits in control groups 1 and 2 by the above-mentioned method, the water-soluble oxide wound dressings of control groups 1 and 2 were applied to the wounds on the skin of New Zealand white rabbits in control groups 1 and 2. The experiment was conducted for a total of 14 days, and the wound areas of the New Zealand white rabbits in each group were measured on the 2nd, 6th, 10th, and 14th days after the application of the dressings, and the results are shown in Table 1 below.
実験群1及び実験群2の相違点は酸素含有量にある。実験群2の酸素含有量は、実験群1より高かった。表1から分かるように、高い酸素含有量は、傷口の閉合率を高めた。また、実験群1及び実験群2は、動物の傷口上をポリウレタン防水フィルムで覆って傷口の湿潤状態を保持した。対照群1及び対照群2は、動物の傷口上をポリウレタン防水フィルムで覆い、表1から分かるように、湿環境下で傷口の癒合速度は速くなった。上述したことから分かるように、傷口の湿性癒合には、以下の長所がある。まず、壊死組織及び繊維タンパクの溶解に有利であり、湿環境下で傷口の滲出液中の組織タンパク質分解酵素は、壊死組織の溶解及び吸収を促進させる。また、創面の酸素分圧を調節し、毛細血管の形成を促進させ、低酸素環境が毛細血管の増殖を刺激し、上皮細胞及びコラーゲンの生成に有利である。滲出液中の多種の成長因子の放出を促進させ、創面中に保留された滲出液を放出するとともに、多種の酵素及び酵素の活性化因子が働き、滲出液が細胞の生存率をさらに高め、多種の成長因子の放出を促進し、細胞の増殖を刺激する。また、創面を恒温状態に維持して細胞分裂を加速させて創面の癒合を促進し、局部的に湿潤状態にして結痂の形成を減らし、新生肉芽組織の機械性損傷を防ぎ、被覆材を交換する際の損傷及び疼痛を低減させ、創面の神経末梢を保護し、疼痛を低減させることができる。密閉性保湿環境を形成し、被覆材でバリアを形成し、傷口から感染するリスクを減らし、密閉状態の微酸環境下で細菌が増殖することを抑制し、白血球を増加させて機能を発揮させることができる。 The difference between experimental group 1 and experimental group 2 is the oxygen content. The oxygen content of experimental group 2 was higher than that of experimental group 1. As can be seen from Table 1, the high oxygen content increased the wound closure rate. In addition, in experimental group 1 and experimental group 2, the wounds of the animals were covered with a polyurethane waterproof film to keep the wound moist. In control group 1 and control group 2, the wounds of the animals were covered with a polyurethane waterproof film, and as can be seen from Table 1, the wound healing speed was faster in a moist environment. As can be seen from the above, moist wound healing has the following advantages. First, it is favorable for dissolving necrotic tissue and fibrous protein, and in a moist environment, the tissue proteolytic enzymes in the wound exudate promote the dissolution and absorption of necrotic tissue. It also regulates the oxygen partial pressure on the wound surface and promotes the formation of capillaries, and the low oxygen environment stimulates the proliferation of capillaries, which is favorable for the production of epithelial cells and collagen. It promotes the release of various growth factors in the exudate, releases the exudate retained in the wound, and activates various enzymes and enzyme activators, which further increase the cell survival rate, promote the release of various growth factors, and stimulate cell proliferation. It also maintains the wound at a constant temperature, accelerates cell division, and promotes wound healing, keeps the wound moist to reduce the formation of eschars, prevents mechanical damage to newly formed granulation tissue, reduces damage and pain when changing dressings, protects the nerve endings of the wound, and reduces pain. It forms an airtight moist environment and a barrier with the dressing, reducing the risk of infection from the wound, inhibits the proliferation of bacteria in an airtight slightly acidic environment, and increases white blood cells to perform its function.
図3を参照する。図3に示すように、本実施形態は、希釈酸化物塩類溶液を活性炭吸着フィルター12に通すステップを行う前に、オゾンを添加するステップをさらに含み、希釈酸化物塩類溶液を添加剤槽16中に導入するとともに、オゾンを添加剤槽16中に加え、オゾンにより希釈酸化物塩類溶液に対して殺菌ステップを行ってもよい。
Refer to FIG. 3. As shown in FIG. 3, this embodiment may further include a step of adding ozone before the step of passing the diluted oxide salt solution through the activated
(人体実験)
図4A～図4Cを参照する。図4A～図4Cに示すように、実験を行う対象は、糖尿病患者の足であり、当該足の腱・靭帯組織は既に破潰され、膿性分泌物及び壊死組織が増えた状態であった。本考案が製造した水溶性酸化物傷口被覆材を患者の患部に貼付し、0～7日の傷口の癒合状態を観察した。100wt%の水溶性酸化物傷口被覆材の総重量パーセントで計算すると、水溶性高分子の総重量パーセントは、30.0%のアルギン酸ナトリウム、25.0%のポリビニルピロリドン及び25.0%のカルボキシメチルセルロースナトリウムを含んだ。貼付して2日後に潰瘍の状態が改善し、貼付して7日後に傷口が徐々に癒合し、傷口の範囲が縮小した。
(Human experimentation)
Please refer to Figures 4A to 4C. As shown in Figures 4A to 4C, the subject of the experiment was a diabetic patient's foot, whose tendon and ligament tissue had already been ruptured, and purulent secretions and necrotic tissues had increased. The water-soluble oxide wound dressing prepared by the present invention was applied to the affected area of the patient, and the wound healing state was observed from 0 to 7 days. Calculated based on the total weight percentage of the water-soluble oxide wound dressing of 100 wt%, the total weight percentage of the water-soluble polymer contained 30.0% sodium alginate, 25.0% polyvinylpyrrolidone, and 25.0% sodium carboxymethylcellulose. After 2 days of application, the ulcer condition improved, and after 7 days of application, the wound gradually healed and the wound area was reduced.
上述したことから分かるように、本考案に係る水溶性酸化物傷口被覆材の製造装置は、当該製造装置で製造した水溶性酸化物傷口被覆材により傷口を湿環境下にし、傷口の滲出液中の組織タンパク質分解酵素が、壊死組織の溶解及び吸収を促進させる。また、低酸素環境により毛細血管の増殖を刺激し、上皮細胞及びコラーゲンの生成に有利である。また、本考案に係る水溶性酸化物傷口被覆材の製造装置は、当該製造装置で製造した水溶性酸化物傷口被覆材により傷口を密閉性保湿環境下にし、被覆材でバリアを形成し、感染するリスクを減らし、密閉状態の微酸環境下で細菌が増殖することを抑制し、白血球を増加させて機能を発揮させる。さらに、本考案に係る水溶性酸化物傷口被覆材の製造装置は、当該製造装置で製造した水溶性酸化物傷口被覆材が、創面中に保留された滲出液を放出するとともに、多種の酵素及び酵素の活性化因子が働き、滲出液が細胞の生存率をさらに高め、多種の成長因子の放出を促進し、細胞の増殖を刺激する。また、本考案に係る水溶性酸化物傷口被覆材は、抗炎症性反応及び傷口の平坦化効果を有するとともに、傷口の癒合を加速させることもできる。 As can be seen from the above, the water-soluble oxide wound dressing manufacturing apparatus according to the present invention uses the water-soluble oxide wound dressing manufactured by the manufacturing apparatus to create a moist wound environment, and the tissue protein decomposition enzymes in the wound exudate promote the dissolution and absorption of necrotic tissue. In addition, the low oxygen environment stimulates the proliferation of capillaries, which is favorable for the production of epithelial cells and collagen. In addition, the water-soluble oxide wound dressing manufacturing apparatus according to the present invention uses the water-soluble oxide wound dressing manufactured by the manufacturing apparatus to create a sealed moist environment for the wound, forming a barrier with the dressing, reducing the risk of infection, inhibiting the proliferation of bacteria in a sealed slightly acidic environment, and increasing the number of white blood cells to perform its function. Furthermore, the water-soluble oxide wound dressing manufactured by the manufacturing apparatus according to the present invention releases the exudate retained in the wound surface, and various enzymes and enzyme activators work, and the exudate further increases the survival rate of cells, promotes the release of various growth factors, and stimulates cell proliferation. In addition, the water-soluble oxide wound dressing of the present invention has an anti-inflammatory reaction and a wound flattening effect, and can also accelerate wound healing.
当該分野の技術を熟知するものが理解できるように、本考案の好適な実施形態を前述の通り開示したが、これらは決して本考案を限定するものではない。本考案の主旨と領域を逸脱しない範囲内で各種の変更や修正を加えることができる。従って、本考案の実用新案登録請求の範囲は、このような変更や修正を含めて広く解釈されるべきである。 The preferred embodiments of the present invention have been disclosed above so that those skilled in the art can understand them, but they are not intended to limit the present invention in any way. Various changes and modifications can be made without departing from the spirit and scope of the present invention. Therefore, the scope of the utility model registration claims of the present invention should be broadly interpreted to include such changes and modifications.
11 収容槽
12 活性炭吸着フィルター
13 電解磁化装置
14 流量制御弁
15 磁化反応器
16 添加剤槽
151 水溶性高分子
11 Containment tank
12 Activated carbon adsorption filter
13 Electromagnetic Magnetizer
14 Flow control valve
15 Magnetized Reactor
16 Additive tank
151 Water-soluble polymers
Claims (4)
前記収容槽には、蒸留水又は鉱泉水を収容し、前記蒸留水又は前記鉱泉水に酸化物塩類水溶液を加え、前記収容槽中で希釈酸化物塩類水溶液を生成し、前記酸化物塩類水溶液は、加熱電解法により高圧酸素を結晶塩水溶液に通して形成し、
前記活性炭吸着フィルターは、前記収容槽に接続し、前記活性炭吸着フィルターにより、前記希釈酸化物塩類水溶液中の微量な疎水性有害物質を除去し、
前記流量制御弁は、前記活性炭吸着フィルターと接続し、前記活性炭吸着フィルターで濾過した後の前記希釈酸化物塩類水溶液の出力流量を制御し、
前記磁化反応器は、前記流量制御弁と接続し、前記流量制御弁が出力した前記希釈酸化物塩類水溶液を受け、前記希釈酸化物塩類水溶液を合成反応させて濃縮活性酸化物水を生成し、
前記濃縮活性酸化物水を水溶性高分子及び前記蒸留水に加えて水溶性酸化物傷口被覆材を形成することを特徴とする、水溶性酸化物傷口被覆材の製造装置。 An apparatus for producing a water-soluble oxide wound dressing, comprising a storage tank, an activated carbon adsorption filter, a flow control valve and a magnetization reactor,
The storage tank contains distilled water or mineral spring water, and an oxide salt aqueous solution is added to the distilled water or the mineral spring water to generate a diluted oxide salt aqueous solution in the storage tank. The oxide salt aqueous solution is formed by passing high-pressure oxygen through the crystallized salt aqueous solution by a thermal electrolysis method.
the activated carbon adsorption filter is connected to the storage tank, and the activated carbon adsorption filter removes trace amounts of hydrophobic harmful substances from the diluted oxide salt aqueous solution;
the flow control valve is connected to the activated carbon adsorption filter and controls the output flow rate of the diluted oxide salt aqueous solution after filtering through the activated carbon adsorption filter;
The magnetization reactor is connected to the flow control valve, receives the diluted oxide salt aqueous solution outputted by the flow control valve, and causes a synthetic reaction of the diluted oxide salt aqueous solution to generate concentrated active oxide water;
The concentrated active oxide water is added to a water-soluble polymer and the distilled water to form a water-soluble oxide wound dressing.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW112114290 | 2023-04-17 | ||
| TW112114290A TWI845257B (en) | 2023-04-17 | Method for manufacturing water solubility oxide wound dressing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP3247048U true JP3247048U (en) | 2024-06-13 |
Family
ID=91377079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001028U Active JP3247048U (en) | 2023-04-17 | 2024-04-02 | Water-soluble oxide wound dressing manufacturing equipment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3247048U (en) |
-
2024
- 2024-04-02 JP JP2024001028U patent/JP3247048U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041438B (en) | Moist antibacterial hydrogel dressing for curing diabetic foot ulcer | |
| EP3695855A1 (en) | Alginate wound repair dressing and preparation method thereof | |
| Chopra et al. | Strategies and therapies for wound healing: a review | |
| Kobayashi et al. | Effects of cholesterol‐bearing pullulan (CHP)‐nanogels in combination with prostaglandin E1 on wound healing | |
| Liu et al. | Research progress on the use of micro/nano carbon materials for antibacterial dressings | |
| KR101710615B1 (en) | Dermal matrix for transplantation having improved survival rate and method for preparing thereof | |
| AU2021105727A4 (en) | A method of preparation of Silk Fibroins coated with Hybrid chitosan-ZnO nanoparticles for wound dressing. | |
| KR100923122B1 (en) | Preparation for wound healing and prevention of bandage adhesion to the wound | |
| JP4486304B2 (en) | Microbial cellulosic wound dressings for the treatment of chronic wounds | |
| WO2020180202A1 (en) | Composition based on cerium dioxide nanoparticles and brown algae polysaccharides for wound treatment | |
| JP3247048U (en) | Water-soluble oxide wound dressing manufacturing equipment | |
| CN109432483B (en) | Medical dressing for accelerating wound healing and preparation method and application thereof | |
| TWI845257B (en) | Method for manufacturing water solubility oxide wound dressing | |
| CN115850733A (en) | Injectable nano clay hydrogel and preparation method and application thereof | |
| TWI804024B (en) | Production method of high oxygen-containing aqueous gel and high-oxygen aqueous gel | |
| CN112870430A (en) | Composite gel hemostatic powder based on natural polysaccharide, and preparation method and application thereof | |
| TWI782850B (en) | Three-dimensional network aqueous gel and method for producing the same | |
| CN113336974B (en) | Easily degradable histidine-based coordination hydrogel with fluidity and preparation method and application thereof | |
| CN108245706B (en) | Bionic skin dressing with 3D micro-pattern structure and preparation method thereof | |
| CN108434512A (en) | A kind of Medical-use cold compress gel and preparation method thereof for post surgery treatment | |
| CN108144100A (en) | A kind of Wound dressing for promoting wound healing and preparation method thereof | |
| CN116019970A (en) | Method for producing high-oxygen-content aqueous gel | |
| CN114452435B (en) | High-affinity liquid dressing capable of being rapidly effective | |
| Chowdhary et al. | Biopolymers for wound healing | |
| CN111821504B (en) | Silver ion disinfection gel and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 3247048 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |